Supplementary File

Article title: Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan

Journal name: Breast Cancer

Author names: Masato Takahashi, Kenichi Inoue, Hirofumi Mukai, Takashi Yamanaka, Chiyomi Egawa, Yasuo Miyoshi, Yukinori Sakata, Kenzo Muramoto, Hiroki Ikezawa, Toshiyuki Matsuoka, Junji Tsurutani

Corresponding author:
Masato Takahashi
Department of Breast Surgery
National Hospital Organization Hokkaido Cancer Center
2-3-54, Kikusuishijo, Shiroishi-ku, Sapporo, Hokkaido 003-0804, Japan
Tel: +81-11-811-9111
Fax: +81-11-811-9153
E-mail: masato.takahashi0725@gmail.com
Table S1. Cutoff value of ALC as a predictor for the effect of eribulin on overall survival

| ALC cutoff (/μL) | n    | Median OS (months) | HR  | 95% CI (Lower) | 95% CI (Upper) | p value |
|-----------------|------|--------------------|-----|----------------|----------------|---------|
| ≥1000           | 359  | 17.3               | 0.695 | 0.560           | 0.862          | p<0.001 |
| <1000 (Ref.)    | 201  | 14.2               |      |                |                |         |
| ≥1100           | 322  | 17.6               | 0.685 | 0.554           | 0.846          | p<0.001 |
| <1100 (Ref.)    | 238  | 14.2               |      |                |                |         |
| ≥1200           | 274  | 18.5               | 0.641 | 0.517           | 0.793          | p<0.001 |
| <1200 (Ref.)    | 286  | 14.2               |      |                |                |         |
| ≥1300           | 237  | 18.5               | 0.673 | 0.541           | 0.837          | p<0.001 |
| <1300 (Ref.)    | 323  | 14.3               |      |                |                |         |
| ≥1400           | 196  | 18.8               | 0.695 | 0.552           | 0.873          | p =0.002 |
| <1400 (Ref.)    | 364  | 14.5               |      |                |                |         |
| ≥1500           | 170  | 19.4               | 0.628 | 0.492           | 0.801          | p<0.001 |
| <1500 (Ref.)    | 390  | 14.3               |      |                |                |         |
| ≥1600           | 144  | 18.5               | 0.691 | 0.537           | 0.891          | p =0.004 |
| <1600 (Ref.)    | 416  | 14.7               |      |                |                |         |
| ≥1700           | 113  | 18.4               | 0.755 | 0.574           | 0.994          | p =0.044 |
| <1700 (Ref.)    | 447  | 15.5               |      |                |                |         |
| ≥1800           | 89   | 18.8               | 0.726 | 0.537           | 0.983          | p =0.037 |
| <1800 (Ref.)    | 471  | 15.5               |      |                |                |         |

ALC, absolute lymphocyte count; CI, confidence interval; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; Ref, reference.
Fig. S1  Overall survival by baseline ALC, NLR, and the number of regimens

ALC, absolute lymphocyte count; CI, confidence interval; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival.